Nutriband Inc. (NasdaqCM: NTRB)
Health Care · Pharmaceuticals · US
$4.88
+4.58% today · -27.1% 1Y
Nutriband Inc. (NasdaqCM: NTRB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $56.72M and employs 13 people.
Over the last twelve months the share price has lost 27.1%, trading between 2.80 and 8.63.
Tweenvest scores Nutriband Inc. across four factors: quality 27/100, value 37/100, growth 18/100. Its strongest factor is value.
NTRB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $56.72M
- Revenue (TTM)
- $1.80M
- P/E
- —
- EPS
- -2.51
- Dividend yield
- —
- Beta (5Y)
- 1.97
- 52-week high
- $8.63
- 52-week low
- $2.80
- Avg volume (3M)
- —
- Shares outstanding
- 12.16M
- Employees
- 13
- Next earnings
- —
About Nutriband Inc.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
- ISIN
- US67092M2089
- Founded
- 2016
- Listed since
- Oct 1, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,253.72 | +0.54% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.95 | -0.03% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.94 | +2.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.45 | +1.72% |
Figures last refreshed Aug 18, 2026.